Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

DSIP

Emideltide, DSIP nonapeptide, Delta sleep-inducing peptide

Quick Stats
Studies 458
Trials 82
Not Yet Recruiting PHASE3 INTERVENTIONAL NCT06212765

Oral Citrulline Supplementation in COPD Patients With Malnutrition

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Chronic obstructive pulmonary disease (COPD) is complicated by malnutrition in 20-70% of cases. In COPD, low fat-free mass is associated with a higher risk of morbidity and mortality. L-citrulline is a non-protein amino acid that has a direct effect on muscle protein synthesis. Oral supplementation with L-citrulline (10 g/day) in malnourished patients has shown to increase fat-free mass. The effects of L-citrulline supplementation in malnourished COPD patients are unknown. The main objective of this prospective, single-centre, randomised, double-blind, placebo-controlled study will be to determine the impact of 45 days of nutritional supplementation with L-citrulline (10 g/day) on lean body mass (fat-free mass index (in kg.m-2) measured by bioelectrical impedance analysis) in malnourished patients (BMI \< 20 kg/m2 if \< 70 years old or \< 22 kg/m2 if ≥ 70 years old) with COPD at stages 3-4 of the GOLD classification.

Interventions

Name: L-citrulline
Type: DRUG
Description: to take 1 pod a day for 45 days

Primary Outcomes

Measure: Fat Free Mass Index
TimeFrame: baseline, 45+/-5 day and 1 year +/- 2 weeks
Description: Fat Free Mass Index (in kg.m-2) measured by bioelectrical impedance analysis

Trial Information

NCT ID

NCT06212765

Status

Not Yet Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

University Hospital, Grenoble

Last Updated

December 15, 2025